IMPACT OF VAGAL NERVE STIMULATION ON QUALITY OF LIFE IN DRUG-RESISTANT EPILEPSY

Background and objective. Vagal nerve stimulation (VNS) represents an alternative therapy for intractable epilepsy. The aim of this study is to analyse seizure reduction and the life quality of these patients. Material and methods. We prospectively examined 28 adult patients treated with VNS that w...

Full description

Bibliographic Details
Main Authors: Nicoleta Tohanean, Cristina Pinzaru, Luminita Mirea, Lacramioara Perju-Dumbrava
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2018-09-01
Series:Romanian Journal of Neurology
Subjects:
Online Access:http://revistemedicale.amaltea.ro/Romanian_Journal_of_NEUROLOGY/Revista_Romana_de_NEUROLOGIE-2018-Nr.3/RJN_2018_3_Art-04.pdf
Description
Summary:Background and objective. Vagal nerve stimulation (VNS) represents an alternative therapy for intractable epilepsy. The aim of this study is to analyse seizure reduction and the life quality of these patients. Material and methods. We prospectively examined 28 adult patients treated with VNS that were followed-up at least 6 months after the surgery and we recorded the number of seizures and any other changes. 16 epilepsy patients completed the Quality of Life in Epilepsy-31 questionnaire (QOLIE-31). Results. Our data revealed that 64% of patients were responders with more than 50% seizure reduction. According to McHugh classifi cation of seizure freedom, 36% patients are in class I (80-100% seizure reduction), 29% class II (50-79% reduction), 21% class III (less than 50% reduction), 7% class IV (magnet benefi t only) and 7% class V (no improvement). Only 8 patients presented mild adverse effects, such as hoarseness, fatigue and cough. Life quality has improved for 68% patients. There is a strong correlation between life quality and health and a mild positive relation with the seizure reduction. Conclusions. VNS improves life quality for more than half of patients and is a therapy to consider in refractory epilepsy.
ISSN:1843-8148
2069-6094